

Global Biosimilars Business and Investment Opportunities - Analysis and Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update

Market Report | 2023-03-24 | 1350 pages | BioIntel360

AVAILABLE LICENSES:

- Single User Price \$8900.00
- Multi User Price \$9900.00
- Enterprise User Price \$11900.00

Report description:

Insights and data in the report have been segmented under the following six modules:

Module 1: Global Biosimilars Funding and Investments Outlook

This module provides insights and data related to biosimilars partnerships and investment (research and development, mergers and acquisitions, product development, commercialization, licensing, and manufacturing) and allows a peek into the futuristic trends of biosimilars technology investment area.

Module 2: Global Biosimilars Clinical Trial Data Assessment

This module evaluates the data available from clinical trials conducted utilising cell and gene technology, representing a bird's eye view of emerging market dynamics and risks in the biosimilars sector.

Module 3: Global Biosimilars Patent Data Analysis

This module presents an exhaustive study of biosimilars patent analytics at various levels, including strategic research planning as well as analyzing their potential applications.

Module 4: Competitive Landscape

This module provides detailed information along with a scoring matrix of key companies related to the biosimilars industry, including their historical performance and the latest developments.

Module 5: Global Biosimilars Market Size and Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

This module provides projections on the market's development during the years 2018-2027 after the profound evaluation of market dynamics at the deeper segmentation level. This report also provides an in-depth, data-centric analysis of the global biosimilars market at regional and country levels:

Biosimilar Market Size By Product

- Monoclonal Antibody Biosimilars
- Insulin Biosimilar
- Biosimilar Interferons
- Other Biosimilar

Biosimilar Market Size By Type of Cell

- Mammalian
- Non-Mammalian

Biosimilar Market Size By Imaging Technique

- Magnetic Resonance Imaging Scanners
- Computed Tomography Scanners
- Positron Emission Tomography Scanners
- Others

Biosimilar Market Size By Procedure

- Invasive
- Non-Invasive

Biosimilar Market Size By Source of Manufacturing

- In-House
- Contract Manufacturing

Biosimilar Market Size By Applications

- Oncology
- Blood Disorders
- Growth Hormonal Deficiency
- Chronic & Autoimmune Disorders
- Infectious Diseases
- Others

Biosimilar Market Size By Type of Technology

- Mass Spectroscopy
- Chromatography
- Recombinant DNA technology
- Electrophoresis
- Others

Biosimilar Market Size By End User

- Hospital & Clinics
- Diagnostic Centres
- Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Biosimilar Market Size By Regions

- North America
 - United States
 - Canada
 - Mexico
- Europe
 - France
 - United Kingdom
 - Germany
 - Italy
 - Spain
- Asia-Pacific
 - China
 - Japan
 - Australia
 - India
 - South Korea
- MEA region
 - Israel
 - South Africa
 - Turkey
 - Saudi Arabia
- Latin America
 - Brazil
 - Argentina
 - Colombia

Key Companies Covered

- Amgen Inc
- Novartis
- Eli Lilly and Company
- Celltrion Inc
- Dr. Reddy's Laboratories Ltd
- Fresenius SE & Co. KGAA
- Samsung Biologics
- Biocon Limited

Module 6 Regulatory Outlook

This module contains a detailed understanding of the ethical, legal, and social implications of biosimilars.

Table of Contents:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

This market intelligence report features an in-depth analysis on the current market dynamics of the biosimilars market.

It provides a detailed analysis of biosimilar market dynamics, covering clinical trials, patent data, financial deals, and competitive landscape through 35 sections, 700+ tables, and 1000+ charts.

Chapter 1 About this Report

- 1.1 Research Methodology
- 1.2 Definitions
- 1.3 Disclaimer

Chapter 2 Global Biosimilars Market Outlook and Future Growth Dynamics

- 2.1 Introduction
- 2.2 Market Opportunities and Growth Dynamics
- 2.3 Regulation and Challenges Related to Biosimilars Around the Globe

Chapter 3 Regulatory Dynamics Assessment Across Different regions

- 3.1 North America Biosimilars Regulations
- 3.2 Europe Biosimilars Regulations
- 3.3 Asia Pacific Biosimilars Regulations
- 3.4 Latin America Biosimilars Regulations
- 3.5 Middle East & Africa region Biosimilars Regulation

Chapter 4 Discovery and Clinical Pipeline Market Attractiveness

- 4.1 Biosimilars Based: Discovery and Clinical Pipeline
- 4.2 FDA Approved Biosimilars, 2017-2022
- 4.3 EMEA Approved Biosimilars, 2017-2022
- 4.4 List of Top 10 Innovation Driving Worldwide Biologics Sales in 2022
- 4.5 List of Biologics Coming Off Patents Between 2023 to 2027

Chapter 5 Global Biosimilars Financial Deals & Alliances Market Dynamics & Outlook

- 5.1 Biosimilars Financial Deals & Alliances Market Prediction and Estimation
- 5.2 Biosimilars Financial Deals Vs Mergers & Acquisition, 2022 vs 2025
- 5.3 Biosimilars Financial Deals Analysis by Type of Cell, 2022 vs 2025
- 5.4 Biosimilars Financial Deals Analysis by Therapeutic Class, 2022 vs 2025
- 5.5 Biosimilars Financial Deals Analysis by Phase-Wise Deals, 2022 vs 2025
- 5.6 Biosimilars Financial Deals Analysis by Type of Procedure, 2022 vs 2025
- 5.7 Biosimilars Financial Deals Analysis by Type of Industry, 2022 vs 2025
- 5.8 Biosimilars Financial Deals Analysis by Region, 2022 vs 2025
- 5.9 Biosimilars Fundings and Investment Analysis by Funding Type, 2018-2022
- 5.10 Biosimilars Fundings and Investment Analysis by Funding Stage, 2018-2022
- 5.11 Recent Deals and Partnerships of Biosimilars
- 5.12 Recent Biosimilars Mergers and Acquisitions
- 5.13 Global Biosimilars Deals Landscape, 2022

Chapter 6 Biosimilars Patent Analysis & Outlook

- 6.1 Biosimilars Historical and Futuristic Trend of Patent, 2018-2027
- 6.2 Biosimilars Patent Analysis by Type of Players, 2022 vs 2025

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3 Biosimilars Patent Analysis by Patent Type, 2018-2022
- 6.4 Biosimilars Patent Analysis by Legal Status, 2018-2022
- 6.5 Biosimilars Patent Analysis by Top Patent Owners
- 6.6 Biosimilars Patent Analysis by Top Patent Applicants
- 6.7 Biosimilars: Biosimilars Top Patent Applicants Benchmarking Analysis
- 6.8 Biosimilars Patent Analysis by Published Status
- 6.9 Biosimilars Patent Analysis by Investors
- 6.10 Biosimilars Patent Analysis by CPC Classification Code
- 6.11 Biosimilars Patent Documents by Jurisdiction
- 6.12 Biosimilars Company Patent Filing Analysis
- 6.13 List of Recent Biosimilars Patents

Chapter 7 Biosimilars Clinical Trial Analysis & Outlook

- 7.1 Biosimilars Clinical Trial Historical and Futuristics Trend
- 7.2 Biosimilars Clinical Trial Region-wise Prediction & Estimation, 2018-2027
- 7.3 Biosimilars Clinical Trial Analysis by Country-wise Analysis
- 7.4 Biosimilars Clinical Trial Analysis by Age Group
- 7.5 Biosimilars Clinical Trial Analysis by Funding Agency
- 7.6 Biosimilars Clinical Trial Analysis by Documents
- 7.7 Biosimilars Clinical Trial Analysis by Diseases-wise
- 7.8 Biosimilars Clinical Trial Analysis by Phase-wise
- 7.9 Biosimilars Clinical Trial Analysis by Status
- 7.10 Biosimilars Clinical Trial Analysis by Study Type
- 7.11 Biosimilars Clinical Trial Analysis by Type of Rare Diseases

Chapter 8 Biosimilars Competitive Landscape Analysis: Key Company Profiles and Strategic Initiatives

- 8.1 Biosimilars Competitive Index Ranking & Attractiveness Quadrant
- 8.2 Biosimilars Company Market Share
- 8.3 Biosimilars Competitive Mapping Quadrant
- 8.4 Biosimilars Competitive Landscape by Count of Biosimilar
- 8.5 Count of Biosimilar Company by Approval Year
- 8.6 Biosimilars Competitive Landscape by Region
- 8.7 Key Companies by Regions
- 8.8 Biosimilar Company Clinical Pipeline Count
- 8.9 Count of Biosimilar by Therapeutics Area
- 8.10 Biosimilars Developers Worldwide
- 8.11 Amgen Inc
- 8.12 Novartis
- 8.13 Eli Lilly and Company
- 8.14 Celltrion Inc
- 8.15 Dr. Reddy's Laboratories Ltd
- 8.16 Fresenius SE & Co. KGAA
- 8.17 Samsung Biologics
- 8.18 Biocon Limited

Chapter 9 Global Biosimilar Market Size and Forecast, 2018-2027

- 9.1 Global Biosimilar Market Size and Forecast, 2018-2027

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2 Global Biosimilar Market Share by Product, 2018-2027
 - 9.2.1 Biosimilar Market Size by Monoclonal Antibody Biosimilars, 2018-2027
 - 9.2.2 Biosimilar Market Size by Insulin Biosimilar, 2018-2027
 - 9.2.3 Biosimilar Market Size by Biosimilar Interferons, 2018-2027
 - 9.2.4 Biosimilar Market Size by Other Biosimilars, 2018-2027
- 9.3 Global Biosimilar Market Share by Monoclonal Antibody Biosimilars, 2018-2027
- 9.4 Biosimilar Market Share by Insulin Biosimilars, 2018-2027
- 9.5 Biosimilar Market Share by Interferons Biosimilars, 2018-2027
- 9.6 Biosimilar Market Share by Other Biosimilars, 2018-2027
- 9.7 Global Biosimilar Market Share by Type of Cell, 2018-2027
 - 9.7.1 Biosimilar Market Size by Mammalian Cell, 2018-2027
 - 9.7.2 Biosimilar Market Size by Non-Mammalian Cell, 2018-2027
- 9.8 Global Biosimilar Market Share by Imaging Technique, 2018-2027
 - 9.8.1 Biosimilar Market Size by Magnetic Resonance Imaging Scanners, 2018-2027
 - 9.8.2 Biosimilar Market Size by Computed Tomography Scanners, 2018-2027
 - 9.8.3 Biosimilar Market Size by Positron Emission Tomography Scanners, 2018-2027
 - 9.8.4 Biosimilar Market Size by Others, 2018-2027
- 9.9 Global Biosimilar Market Share by Procedure, 2018-2027
 - 9.9.1 Biosimilar Market Size by Invasive Procedure, 2018-2027
 - 9.9.2 Biosimilar Market Size by Non-Invasive Procedure, 2018-2027
- 9.10 Global Biosimilar Market Share by Source of Manufacturing, 2018-2027
 - 9.10.1 Biosimilar Market Size by In-House, 2018-2027
 - 9.10.2 Biosimilar Market Size by Contract Manufacturing, 2018-2027
- 9.11 Global Biosimilar Market Share by Applications, 2018-2027
 - 9.11.1 Biosimilar Market Size by Oncology, 2018-2027
 - 9.11.2 Biosimilar Market Size by Blood Disorders, 2018-2027
 - 9.11.3 Biosimilar Market Size by Growth Hormonal Deficiency, 2018-2027
 - 9.11.4 Biosimilar Market Size by Chronic & Autoimmune Disorders, 2018-2027
 - 9.11.5 Biosimilar Market Size by Infectious Diseases, 2018-2027
 - 9.11.6 Biosimilar Market Size by Others, 2018-2027
- 9.12 Global Biosimilar Market Share by Type of Technology, 2018-2027
 - 9.12.1 Biosimilar Market Size by Mass Spectroscopy, 2018-2027
 - 9.12.2 Biosimilar Market Size by Chromatography, 2018-2027
 - 9.12.3 Biosimilar Market Size by Recombinant DNA Technology, 2018-2027
 - 9.12.4 Biosimilar Market Size by Electrophoresis, 2018-2027
 - 9.12.5 Biosimilar Market Size by Others, 2018-2027
- 9.13 Global Biosimilar Market Share by End User, 2018-2027
 - 9.13.1 Biosimilar Market Size by Hospital & Clinics, 2018-2027
 - 9.13.2 Biosimilar Market Size by Diagnostic Centres, 2018-2027

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.13.3 Biosimilar Market Size by Others, 2018-2027

Chapter 10 - Chapter 35: This section contains chapters providing biosimilar market sizing and forecast for additional 20 countries and 5 regions.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Biosimilars Business and Investment Opportunities - Analysis and Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update

Market Report | 2023-03-24 | 1350 pages | BioIntel360

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|-----------------------|------------|
| | Single User Price | \$8900.00 |
| | Multi User Price | \$9900.00 |
| | Enterprise User Price | \$11900.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|---|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | <input type="text" value="2026-03-02"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.